11 results
Industry
PROJECT NUMBER • 2014-242
PROJECT STATUS:
COMPLETED

Commercialising the production of Cobia in Australia

This project is a collaboration between the Department of Agriculture and Fisheries (DAF) and the Cobia aquaculture sector, predominantly Pacific Reef Fisheries (PRF). It was undertaken to consolidate the aquaculture in Australia of Cobia, a species offering considerable potential as a...
ORGANISATION:
Department of Primary Industries (QLD)
SPECIES
Industry
PROJECT NUMBER • 2019-088
PROJECT STATUS:
COMPLETED

Development of a national sector-specific biosecurity plan guideline and template for the sea-cage finfish (non-salmonid) industry of Australia.

In this project, we developed guidelines to provide the Australian sea-cage finfish (non-salmonid) industry with the tools and templates to create an auditable farm biosecurity plan. Consideration was given to the current farming of yellowtail kingfish (Seriola lalandi), southern bluefin tuna...
ORGANISATION:
University of Adelaide
Industry
PROJECT NUMBER • 2017-103
PROJECT STATUS:
COMPLETED

The evaluation of two species, Cobia and Giant Grouper, as alternative species to farm in the WSSV affected areas of South East Queensland.

In 2016/17, the Rocky Point Prawn Farm, along with other farms in the Logan River region of south-east Queensland, was severely affected by a white spot disease outbreak caused by the exotic white spot syndrome virus (WSSV). Measures enforced to eradicate WSSV resulted in a complete loss of stock...
ORGANISATION:
Rocky Point Aquaculture Company Pty Ltd
SPECIES
Industry
PROJECT NUMBER • 2018-157
PROJECT STATUS:
CURRENT

Evaluation of Cobia and Giant Groper production and health in multiple growout systems, as an alternative species to farm in WSSV affected areas of South East Queensland

The report details the production performance and health performance of Cobia (Rachycentron canadum) and Giant Groper (Epinephelus lanceolatus) reared in tanks, ponds and cages within a farm in the previously white spot syndrome virus affected region of the Logan River, Queensland. Findings of this...
ORGANISATION:
Rocky Point Aquaculture Company Pty Ltd
SPECIES
Industry
PROJECT NUMBER • 2019-106
PROJECT STATUS:
COMPLETED

Minor use permit for oxytetracycline in non-salmonid finfish

There are no registered or permitted antimicrobial products approved by the Australian Pesticide and Veterinary Medicine Authority (APVMA) for treatment of bacterial infections in finfish. This project developed an application for a minor-use permit (MUP) for the use of oxytetracycline (OTC) to...
ORGANISATION:
University of Adelaide

Minor use permit for erythromycin in finfish

Project number: 2021-027
Project Status:
Current
Budget expenditure: $95,000.00
Principal Investigator: Marty R. Deveney
Organisation: University of Adelaide
Project start/end date: 21 Oct 2021 - 30 Jul 2022
Contact:
FRDC

Need

There are no antimicrobials permitted or registered for use in finfish in Australia effective against gram positive bacteria (e.g. Streptococcus and Lactococcus). In finfish aquaculture, erythromycin (ERYC) is the best antimicrobial against gram positive organisms. The aquaculture industry and the Subcommittee for Aquatic Animal Health identified access to this product for finfinfish as a priority. Bacterial diseases are increasingly managed by eradication, maintenance of animals of specified health status, vaccination, and good hygiene, but antimicrobial therapy remains vital for treating bacterial diseases in finfish aquaculture. Appropriate use of antimicrobials can alleviate illness and suffering, improve welfare, increase speed of recovery, reduce spread of infection. Use of ERYC is not intended for prophylactic treatment, but as a tool for veterinarians to manage disease outbreaks. Use in South Australia, for example, is sporadic (~1 to 2 times per 3-5 years for a sector). The Aquaculture industry is committed to Australia's antimicrobial strategy, and as required by APVMA this proposal includes an antimicrobial resistance risk assessment. Available data for ERYC can satisfy the APVMA module requirements for efficacy, chemistry and manufacture, toxicology, trade and occupational health and safety. These are available in published literature, a range of industry studies of animals treated off-label and laboratory studies. There is a lack of data to satisfy the requirements mainly in the environment modules and the antimicrobial resistance risk assessment.

ERYC was ranked low by the Expert Advisory Group on Antimicrobial Assessment (EAGAR) as an antimicrobial for which there are a reasonable number of alternative agents in different classes available to treat most infections. Although it is listed on the WHO list of essential medicines, it is registered for use in cattle, pigs and sheep (APVMA #84160) and poultry (APVMA #50742) in Australia and the WHO list can be modified locally to suit the availability and sophistication of the animal and human health systems in WHO member countries. The APVMA PAA assessed ERYC as suitable for assessment for use in finfish.

Objectives

1. Obtain data to satisfy identified gaps and collate available data to satisfy requirements of minor use permit application.
2. Collate and submit minor use permit application.
Industry
Adoption
PROJECT NUMBER • 2018-098
PROJECT STATUS:
COMPLETED

Vaccination for emergency and long-term control of nodavirus in Australian marine aquaculture

Rocky Point Aquaculture in southeast Queensland experienced a disease outbreak in cage-reared giant grouper (Epinephelus lanceolatus) in late summer and autumn 2018 resulting is severe losses caused by a Betanodavirus. Following a request from the farm owner, Serena Zipf in July 2018, Dr Andrew...
ORGANISATION:
University of Queensland (UQ)
SPECIES
View Filter